

Linear and Non-linear associations between vitamin D and grip strength: a Mendelian Randomisation study in UK Biobank

Snehal M Pinto Pereira PhD^{1*}, Victoria Garfield PhD², Thomas Norris PhD¹, Stephen Burgess PhD³, Dylan M Williams PhD², Richard Dodds PhD^{4,5}, Avan A Sayer PhD^{4,5}, Sian M Robinson PhD^{4,5}, Rachel Cooper PhD^{4,5}

¹Institute of Sport, Exercise and Health, Division of Surgery & Interventional Science, University College London, London, United Kingdom

²MRC Unit for Lifelong Health and Ageing at UCL, London, United Kingdom

³MRC Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, UK

⁴AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

⁵NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

*Corresponding author. Address as above; Email: snehal.pereira@ucl.ac.uk

© The Author(s) 2022. Published by Oxford University Press on behalf of The Gerontological Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Low vitamin D status is a widespread phenomenon. Similarly, muscle weakness, often indicated by low grip strength, is another public health concern; however, the vitamin D—grip strength relationship is equivocal. It is important to understand whether variation in vitamin D status causally influences muscle strength to elucidate whether supplementation may help prevent/treat muscle weakness.

Methods: UK Biobank participants, aged 37-73 years, with valid data on Vitamin D status (circulating 25-hydroxyvitamin D (25(OH)D) concentration) and maximum grip strength were included (N=368,890). We examined sex-specific cross-sectional associations between 25(OH)D and grip strength. Using Mendelian randomisation (MR), we estimated the strength of the 25(OH)D—grip strength associations using genetic instruments for 25(OH)D as our exposure. Crucially, because potential effects of vitamin D supplementation on strength could vary by underlying 25(OH)D status, we allowed for non-linear relationships between 25(OH)D and strength in all analyses.

Results: Mean(SD) of 25(OH)D was 50(21)nmol/L in males and females. In cross-sectional analyses there was evidence of non-linear associations between 25(OH)D and strength: e.g., compared to males with 50nmol/L circulating 25(OH)D, males with 75nmol/L had 0.36kg (0.31,0.40) stronger grip; males with 25nmol/L had 1.01kg (95% CI: 0.93,1.08) weaker grip. In MR analyses, linear and non-linear models fitted the data similarly well: e.g., 25nmol/L higher circulating 25(OH)D in males was associated with 0.25kg (-0.05,0.55) greater grip (regardless of initial 25(OH)D status). Results were similar, albeit weaker, for females.

Conclusions: Using two different methods to triangulate evidence, our findings suggest moderate to small causal links between circulating 25(OH)D and grip strength.

Key words: 25(OH)D, grip strength, Mendelian randomisation

Introduction

Low vitamin D status is a widespread phenomenon(1) although status can be improved with supplementation. Muscle weakness, often indicated by low grip strength, is another public health concern. Its prevalence increases at older ages, and it is a key component of age-related conditions such as sarcopenia and frailty(2, 3). The burden of muscle weakness is experienced by individuals, their families and society, and, due to the ageing population, this global burden is expected to rise.

Vitamin D receptors have been identified in muscle cells(4, 5), lending plausibility to the hypothesis that vitamin D plays a role in normal muscle function. While underlying mechanisms are not fully understood, current evidence suggests important genomic and non-genomic effects of vitamin D, with deficiency proposed to lead to increased muscle protein breakdown, impaired mitochondrial function and greater muscle adiposity(6). Cellular and animal studies suggest that muscle responds to vitamin D(7), with the implication that supplementation could prevent/treat muscle weakness. However, the relationship between vitamin D status and muscle strength in humans is equivocal. For example, while a systematic review and meta-analysis of 29 randomized controlled trials (mean age: 61.1 years) reported a small benefit of vitamin D supplementation on muscle strength(8), a reanalysis removing data from two studies that have been retracted or had unresolved data irregularities found no relationship(9). Similarly, no evidence of effect was found in a recent trial of vitamin D supplementation over a 4-month period, among 40–80-year-old community dwelling adults with low vitamin D status at baseline(10). There are several potential reasons for the lack of consensus regarding the relationship between vitamin D and strength including the fact that effects of supplementation may only become apparent after a long duration, with trials not of sufficient length. Observational studies of circulating 25-hydroxyvitamin D concentration (25(OH)D; an established marker for vitamin D status) and muscle strength

may be limited by issues such as residual and unmeasured confounding by, for example, body composition. Thus, a recent Mendelian randomisation (MR) analysis in UK Biobank was important in providing evidence of a modest association between higher lifetime 25(OH)D concentrations and stronger grip(11). While this MR study provided evidence of an association that was less subject to confounding, it assumed a linear dose-response relationship. However, observational studies suggest that the relationship could vary by age and underlying 25(OH)D exposure(8). Thus, examining associations assuming (i) stability across the life-course and (ii) linearity, might not provide an accurate picture of the dose-response relationship between vitamin D and strength. It is therefore imperative to understand whether variation in vitamin D exposure causally influences muscle strength taking account of these two factors.

Given current knowledge gaps, we aimed to establish the causal role of vitamin D on grip strength using UK Biobank data. Our approach is one of triangulation(12), where we obtain more robust evidence by integrating results using different methodologies (observational and genetic). Each methodology has different key sources of potential bias that are unrelated to each other, and, if the results from our different methodological approaches are consistent, it strengthens confidence with respect to causality of our findings. In our observational analysis, we examined cross-sectional associations between circulating concentrations of 25(OH)D and grip strength. Acknowledging the suggestion that the effect of vitamin D supplementation on muscle strength is greater in persons with low baseline 25(OH)D(8), we allowed for non-linear relationships in our analysis. To explore whether associations between 25(OH)D and strength vary by age(8), we reran analyses stratified by four age-groups. To triangulate evidence, we used MR to estimate the strength of the association using genetic instruments for 25(OH)D; crucially, we used MR methods that allowed us to assess non-linear effects of vitamin D on grip strength.

Methods

UK Biobank(13, 14) is a prospective study of over 500,000 UK adults aged 37-73y at recruitment (2006-2010). Participants recruited across the UK from National Health Service central registers, provided informed consent; ethical approval was given by the Northwest Multicentre Research Ethics Committee. The genome-wide association study (GWAS) used to identify our genetic instrument (described below) was primarily based on samples of European ancestry. Hence, we examine data from participants of European ethnicity and our analytical sample with valid genotype data, measures of grip strength, 25(OH)D and no missing covariates was 368,890.

Vitamin D 25(OH)D concentrations were measured in blood samples collected at the initial assessment visit (2006-2010). The DiaSorin Liaison XL, a chemiluminescent immunoassay, was used for the quantitative determination of total 25(OH)D, with a validated range for the assay of 10nmol/L to 375nmol/L. The average within-laboratory coefficient of variation (and standard deviation (SD)) ranged from 5.04 (4.73) to 6.14 (2.21)(15).

Grip strength in kilograms was assessed, once in each hand while seated, at the initial visit, using a Jamar J00105 hydraulic hand dynamometer(16). We examined the maximum recorded value (greater than 0).

Covariates were identified *a priori* and included established determinants of circulating 25(OH)D and potential confounders. Calendar month of assessment visit and vitamin D supplementation (consumed a multivitamin or vitamin D supplement in the previous 24-hours; regular supplementation with vitamin D or self-reported medical treatment with vitamin D products) were considered established determinants of 25(OH)D; potential confounders included age, smoking status, body mass index (BMI; (kg/m²) ascertained following standardised protocols(13)) and the Townsend score (area level indicator of socioeconomic deprivation)(17).

Genetic instrument for circulating 25(OH)D concentration was constructed using six variants that attained genome-wide significance ($p < 5 \times 10^{-8}$) for circulating levels of 25(OH)D in a GWAS of 79,366 European-ancestry individuals(18). We used linkage disequilibrium clumping in PLINK 1.9 to ensure these variants were independent ($r^2 \leq 0.01$, 250kb). In the GWAS these variants explained 2.84% of the variability in circulating 25(OH)D; see Supplementary table 1 for further information. Our genetic instrument is a weighted genetic score constructed by computing the weighted average of the number of 25(OH)D increasing alleles for an individual, where the weight for each SNP was the effect estimate of the association of the SNP with circulating 25(OH)D (on the natural log scale) reported in the GWAS(18).

Statistical methods

Due to marked sex differences in the distribution of grip strength(19), we chose *a priori* to sex-stratify all analyses.

Observational: The associations between circulating 25(OH)D concentration and grip strength were examined by fitting linear regression models, adjusting for covariates listed above. Fractional polynomials were used to determine the appropriate functional form for circulating 25(OH)D concentrations(20). Using likelihood ratio tests, the best-fitting fractional polynomial was determined by comparing the best-fitting fractional polynomials of 1 and 2 degrees. We compared model fit between the best-fitting fractional polynomial and linear models, taking $p < 0.05$ to indicate a non-linear association. To assess whether associations between 25(OH)D and grip strength vary by age, we reran analyses stratified by age-groups representing approximate fourths of the population (i.e., <50y, 50-59y, 60-64y, 65y+), with tests of interaction between age and circulating 25(OH)D concentration formally assessed.

Non-linear MR: We used the fractional polynomial method to capture non-linear genetic associations(21), with a reference point at 50nmol/L(22). We stratified our sample into 100 strata using the doubly-ranked method, whereby we first ranked participants into pre-strata according to their level of the weighted genetic score and then ranked participants within each pre-stratum according to their level of 25(OH)D(23). Within each stratum, we estimate the localized average causal effect (LACE), which is the ratio of coefficients of the regressions of weighted genetic score on grip strength within the stratum to the regression of weighted genetic score on 25(OH)D in the whole population. Both regressions were adjusted for circulating 25(OH)D determinants (month of blood draw, vitamin D supplementation) and genetic ancestry (10 genetic principal components). Next, because the causal effect of circulating 25(OH)D on grip strength (i.e., LACE) is an estimate of the slope of the exposure-

outcome relationship, we regressed stratum-specific mean 25(OH)D against LACE estimates, using a fractional polynomial function (selecting the best-fitting model based on the likelihood ratio test). The integral of the selected fractional polynomial represents the relationship between circulating 25(OH)D and grip strength. The fractional polynomial test is reported for non-linearity, which compares the best-fitting fractional polynomial of degree 1 against the linear model(21). When there was no evidence favouring a non-linear relationship (over a linear relationship) between 25(OH)D and grip strength, we performed a linear MR using the weighted genetic score as our instrument.

Sensitivity analysis and instrument validation

Our MR analyses could be biased in the presence of horizontal pleiotropy, i.e., where the genetic instrument influences grip strength through pathways other than via circulating 25(OH)D. To assess the potential for pleiotropy, we examined whether our genetic instrument was associated with potential confounders in the entire sample. We also reran our MR analyses using a larger weighted genetic score, based on a more recent 25(OH)D GWAS(24) which included UK Biobank participants (details in supplementary text A).

Results

Mean maximum grip strength was higher in males (41.9kg; SD=8.9kg) than females (25.2kg; SD=6.3kg), whereas mean 25(OH)D was approximately 50nmol/L in both sexes (Table 1).

Observational associations: measured 25(OH)D—grip strength

In both sexes, there was evidence of a non-linear association ($p_{\text{non-linear}} < 0.001$) between 25(OH)D and grip strength (Figures 1(a) and 2(a); Supplementary Table 2). For example, compared to males with 50nmol/L of circulating 25(OH)D, males with circulating 25(OH)D at 25nmol/L had 1.01kg (95% CI: 0.93,1.08) weaker grip, those with circulating 25(OH)D at 75 nmol/L had 0.36kg (0.31,0.40) stronger grip. Compared to females with 50nmol/L, females with circulating 25(OH)D at 25nmol/L had 0.19kg (0.15,0.24) weaker grip; females with 25(OH)D at 75 nmol/L also had weaker grip (by 0.07kg (0.03, 0.11)). In both sexes, there was evidence that circulating 25(OH)D—grip strength associations varied by age ($p_{\text{interaction}} < 0.001$; Supplementary Table 3); whereby the circulating 25(OH)D—grip strength slope was shallower (i.e., less steep) with increasing age (Figures 3 and 4).

Linear and non-linear MR associations: genetically predicted 25(OH)D—grip strength

In males and females the linear and non-linear models fitted the data similarly well (Figures 1(b) and 2(b), $p_{\text{non-linear}} = 0.49(\text{males})/0.92(\text{females})$). Based on the linear MR analysis, 25nmol/L higher circulating 25(OH)D was associated with 0.25kg (-0.05,0.55) and 0.14kg (-0.07,0.36) greater grip in males and females respectively (regardless of initial 25(OH)D status) (Supplementary Table 4).

Sensitivity analysis and instrument validation

In our analytical sample, our weighted genetic score explained 2.61% of the variability in circulating levels of 25(OH)D in males and 2.37% in females. The F-statistic was 4,615.22 (males) and 4,772.91 (females). There was some evidence that our weighted genetic score

was associated with potential confounders in UK Biobank, albeit differently by sex (Supplementary Table 5). When we reran the non-linear and linear MR using the larger instrument, results were broadly similar to those reported above (Supplementary text A). For example, the linear and non-linear models fitted the data similarly well ($p_{\text{non-linear}}=0.30(\text{males})/0.11(\text{females})$; Supplementary Figure 1) and a 25nmol/L higher circulating 25(OH)D was associated with 0.28kg (0.04,0.52) and 0.03kg (-0.14,0.20) greater grip in males and females respectively (Supplementary Table 4).

Discussion

We investigated associations between circulating 25(OH)D and grip strength in UK Biobank using two complementary approaches and examined whether non-linear associations were evident. While our observational and genetic analyses did not concur with respect to the shape of the 25(OH)D—grip strength association, they agreed in terms of noting stronger association in males compared to females and generally a positive (i.e., increasing) relationship between 25(OH)D and grip strength in males. As such, using two different methods to triangulate evidence, our findings suggest causal links between circulating 25(OH)D and grip strength, but, in terms of magnitude, our findings suggest vitamin D has a moderate to small impact on grip strength.

Our study has several strengths. For example, our MR associations are subject to less confounding and reverse causation inherent in cross-sectional observational analysis and, UK Biobank's large sample size allowed us to increase the statistical power of our analysis, mitigating against weak instrument bias(25, 26). Our focused 25(OH)D genetic instrument

based on 6 SNPs, provided strong statistical power, instrument strength and biological specificity, minimising the potential for bias due to the use of weak instruments and horizontal pleiotropy arising from using many variants that do not have specific effects on vitamin D pathways. There was only weak evidence that our focused score was associated with potential confounders, providing empirical evidence against horizontal pleiotropy although unmeasured confounding may exist. Moreover, when we repeated our genetic analysis with a larger instrument based on 98 SNPs, our results were near identical, providing further evidence of the robustness of our MR findings. Our observational analysis was cross-sectional and although direction of causality cannot be inferred from such study designs, links between grip strength and subsequent 25(OH)D concentrations in this relatively young and healthy population are less likely to be operating than associations in the direction we have assumed. However, our findings do not negate the potential for a causal association from muscle weakness to low levels of 25(OH)D because, for example, low muscle strength may be associated with spending less time outdoors. Our observational analysis could also be affected by residual confounding, for example, while we accounted for BMI, we did not consider lean and fat mass (which could confound the 25(OH)D—strength association(27, 28)). Our 25(OH)D analyses are limited in their ability to elucidate causal effects of the biologically active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-OH₂D), which correlates better with muscle strength than 25(OH)D(29). However, studies suggest the association between 25(OH)D and 1,25-OH₂D with sarcopenia are independent(30), thus, their influence on muscle strength may also be independent. We were limited to using grip strength as our single measure of muscle strength as the strength of other muscles have not been assessed in UK Biobank. Although grip strength is a convenient and commonly used proxy for overall body strength and the Jamar dynamometer has good reliability and reproducibility(31), we acknowledge that grip strength is a measure of upper limb strength

and evidence on whether it is an adequate proxy for overall muscle strength is equivocal(32, 33). In addition, due to limited data availability, it was not feasible to examine other aspects of muscle, such as muscle mass. Our analysis was restricted to white Europeans, and we are unable to extrapolate to other ethnic groups, which is particularly relevant because markers of vitamin D metabolism vary significantly by ethnicity(34). Additionally, patterns of selection into studies such as UK Biobank(35) can induce collider bias. Even modest influences on selection could lead to biased estimates(36), and we acknowledge that such biases can affect both observational and MR analyses(37). Therefore, future work needs to assess whether our findings replicate in other samples including those representing other ethnic groups and, potentially, geographical regions.

To our knowledge, this is the first study triangulating evidence on the shape of the 25(OH)D—grip strength association and while our observational and genetic analyses did not concur with respect to the shape, the analyses did concur with respect to suggesting vitamin D has a moderate to small impact on grip strength. For example, compared to males with 50nmol/L circulating 25(OH)D, males with 75nmol/L had 0.36/0.25kg stronger grip; males with 25nmol/L had 1.01/0.25kg weaker grip (observational/genetic association). While severe vitamin D deficiency is rare, low status is common: 24% to 40% of American, Canadian and European populations have circulating 25(OH)D levels below 50nmol/L(38); and 13% to 16% of UK adults have 25(OH)D levels below 25nmol/L(39). Therefore, at the population level, our findings have important implications.

Our cross-sectional observational results conflict with previous reports that the relationship between vitamin D supplementation and muscle strength is stronger at older ages(8).

However, our observational analysis was limited in terms of the age range examined and our MR analysis cannot inform on whether the shape and strength of the relationship between circulating 25(OH)D and grip varies by life-stage. Thus, future work needs to examine if the magnitude and shape of the 25(OH)D—strength relationship varies over a wider age-range. It is important to also appreciate that our observational and genetic findings are not interchangeable: the former examines 25(OH)D at the time of blood draw, whereas the latter represents lifelong differences in 25(OH)D levels, rather than a more transient short-term exposure; this difference may explain (in part) why our observational and genetic findings do not concur with respect to the shape of the 25(OH)D—strength relationship. Finally, our findings concur with a previous MR demonstrating a beneficial effect of 25(OH)D on grip strength in UK Biobank(11); however, we add new knowledge by considering the shape of the causal relationship between 25(OH)D concentrations and grip strength and quantifying the scale of the association.

Our findings have potential implications for the aetiological understanding of muscle weakness and its treatment and prevention. Vitamin D supplementation is of considerable interest, as demonstrated by recent calls for evidence on how to improve the vitamin D status of the English population(39). While our results suggest causal links between circulating 25(OH)D and grip strength, they imply that vitamin D supplementation may only have a moderate to small effect on strength.

Conflict of interest: We declare no competing interests.

Funding: The work was supported by a UK Medical Research Council Career Development Award (ref: MR/P020372/1) to SMPP. VG was supported by a joint Diabetes UK (ref: 15/0005250) /British Heart Foundation grant (ref: SP/16/6/32726) and a Professor David Matthews Non-Clinical Fellowship from the Diabetes Research and Wellness Foundation (ref: SCA/01/NCF/22). SB is supported by the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7) and the National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014). RD, AAS, SR and RC are supported by the National Institute for Health and Care Research Newcastle Biomedical Research Centre. The views expressed in the publication are those of the authors and not necessarily those of the funders. The funders had no input into study design; data collection, analysis, and interpretation; in the writing of the report; and in the decision to submit the article for publication. Researchers were independent of influence from study funders.

Acknowledgements: This work was conducted under the approved UK Biobank project number 71702. We thank the volunteer participants of the UK Biobank, and the UK Biobank researchers.

References

1. Lips P; Worldwide status of vitamin D nutrition. *J Steroid Biochem Mol Biol* 2010;**121**(1-2):297-300. doi: 10.1016/j.jsbmb.2010.02.021.
2. Keevil VL, Romero-Ortuno R; Ageing well: a review of sarcopenia and frailty. *Proc Nutr Soc* 2015;**74**(4):337-47. doi: 10.1017/S0029665115002037.
3. Cruz-Jentoft AJ, Sayer AA; Sarcopenia. *Lancet* 2019;**393**(10191):2636-2646. doi: 10.1016/S0140-6736(19)31138-9.
4. Bischoff-Ferrari HA, Borchers M, Gudat F, et al.; Vitamin D receptor expression in human muscle tissue decreases with age. *J Bone Miner Res* 2004;**19**(2):265-9. doi: 10.1359/jbmr.2004.19.2.265.
5. Girgis CM, Mokbel N, Cha KM, et al.; The vitamin D receptor (VDR) is expressed in skeletal muscle of male mice and modulates 25-hydroxyvitamin D (25OHD) uptake in myofibers. *Endocrinology* 2014;**155**(9):3227-37. doi: 10.1210/en.2014-1016.
6. Bollen SE, Bass JJ, Fujita S, et al.; The Vitamin D/Vitamin D receptor (VDR) axis in muscle atrophy and sarcopenia. *Cell Signal* 2022;**96**:110355. doi: 10.1016/j.cellsig.2022.110355.
7. Girgis CM, Clifton-Bligh RJ, Hamrick MW, et al.; The roles of vitamin D in skeletal muscle: form, function, and metabolism. *Endocr Rev* 2013;**34**(1):33-83. doi: 10.1210/er.2012-1012.
8. Beaudart C, Buckinx F, Rabenda V, et al.; The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab* 2014;**99**(11):4336-45. doi: 10.1210/jc.2014-1742.
9. Avenell A, Bolland MJ, Grey A; Population vitamin D supplementation in UK adults: too much of nothing? *Drug Ther Bull* 2021;**59**(1):7-12. doi: 10.1136/dtb.2020.000060.

10. Grimnes G, Kubiak J, Jorde R; Four months vitamin D supplementation to vitamin D insufficient individuals does not improve muscular strength: A randomized controlled trial. *PLoS One* 2019;**14**(12):e0225600. doi: 10.1371/journal.pone.0225600.
11. Mazidi M, Davies IG, Penson P, et al.; Lifetime serum concentration of 25-hydroxyvitamin D 25(OH) is associated with hand grip strengths: insight from a Mendelian randomisation. *Age Ageing* 2022;**51**(4). doi: 10.1093/ageing/afac079.
12. Lawlor DA, Tilling K, Davey Smith G; Triangulation in aetiological epidemiology. *Int J Epidemiol* 2016;**45**(6):1866-1886. doi: 10.1093/ije/dyw314.
13. UK Biobank: Protocol for a large-scale prospective epidemiological resource *UK Biobank Coordinating Centre*, 2007.
14. Sudlow C, Gallacher J, Allen N, et al.; UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015;**12**(3):e1001779. doi: 10.1371/journal.pmed.1001779.
15. Fry Daniel, Almond Rachael, Moffat Stewart, et al.; UK Biobank Biomarker Project: Companion Document to Accompany Serum Biomarker Data. 2019.
16. UK Biobank. UKB : Resource 100232: Grip-strength measurement using ACE. 2011.
17. Townsend P; Deprivation. *Journal of Social Policy* 1987;**16**:125-146. doi: Doi 10.1017/S0047279400020341.
18. Jiang X, O'Reilly PF, Aschard H, et al.; Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. *Nat Commun* 2018;**9**(1):260. doi: 10.1038/s41467-017-02662-2.
19. Dodds RM, Syddall HE, Cooper R, et al.; Grip strength across the life course: normative data from twelve British studies. *PLoS One* 2014;**9**(12):e113637. doi: 10.1371/journal.pone.0113637.

20. Royston P, Altman DG; Regression Using Fractional Polynomials of Continuous Covariates - Parsimonious Parametric Modeling. *Journal of the Royal Statistical Society Series C-Applied Statistics* 1994;**43**(3):429-467.
21. Staley JR, Burgess S; Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. *Genet Epidemiol* 2017;**41**(4):341-352. doi: 10.1002/gepi.22041.
22. Lips P, Cashman KD, Lamberg-Allardt C, et al.; Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. *Eur J Endocrinol* 2019;**180**(4):P23-P54. doi: 10.1530/EJE-18-0736.
23. Tian H MA, Liu C, Burgess S; Relaxing parametric assumptions for non-linear Mendelian randomization using a doubly-ranked stratification method. *bioRxiv* 2022. doi: 10.1101/2022.06.28.497930.
24. Revez JA, Lin T, Qiao Z, et al.; Genome-wide association study identifies 143 loci associated with 25 hydroxyvitamin D concentration. *Nat Commun* 2020;**11**(1):1647. doi: 10.1038/s41467-020-15421-7.
25. Burgess S, Thompson SG; Bias in causal estimates from Mendelian randomization studies with weak instruments. *Stat Med* 2011;**30**(11):1312-23. doi: 10.1002/sim.4197.
26. Burgess S, Thompson SG, Collaboration CCG; Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol* 2011;**40**(3):755-64. doi: 10.1093/ije/dyr036.
27. Perez-Lopez FR, Chedraui P, Pilz S; Vitamin D supplementation after the menopause. *Ther Adv Endocrinol Metab* 2020;**11**:2042018820931291. doi: 10.1177/2042018820931291.

28. Pinto Pereira SM, Garfield V, Farmaki AE, et al.; Adiposity and grip strength: a Mendelian randomisation study in UK Biobank. *BMC Med* 2022;**20**(1):201. doi: 10.1186/s12916-022-02393-2.
29. Hassan-Smith ZK, Jenkinson C, Smith DJ, et al.; 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 exert distinct effects on human skeletal muscle function and gene expression. *PLoS One* 2017;**12**(2):e0170665. doi: 10.1371/journal.pone.0170665.
30. Hirani V, Cumming RG, Naganathan V, et al.; Longitudinal Associations Between Vitamin D Metabolites and Sarcopenia in Older Australian men: The Concord Health and Aging in Men Project. *J Gerontol A Biol Sci Med Sci* 2017;**73**(1):131-138. doi: 10.1093/gerona/glx086.
31. Roberts HC, Denison HJ, Martin HJ, et al.; A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age Ageing* 2011;**40**(4):423-9. doi: 10.1093/ageing/afr051.
32. Bohannon RW, Magasi SR, Bubela DJ, et al.; Grip and knee extension muscle strength reflect a common construct among adults. *Muscle Nerve* 2012;**46**(4):555-8. doi: 10.1002/mus.23350.
33. Yeung SSY, Reijnierse EM, Trappenburg MC, et al.; Handgrip strength cannot be assumed a proxy for overall muscle strength. *J Am Med Dir Assoc* 2018;**19**(8):703-709. doi: 10.1016/j.jamda.2018.04.019.
34. Hsu S, Hoofnagle AN, Gupta DK, et al.; Race, Ancestry, and Vitamin D Metabolism: The Multi-Ethnic Study of Atherosclerosis. *J Clin Endocrinol Metab* 2020;**105**(12). doi: 10.1210/clinem/dgaa612.
35. Fry A, Littlejohns TJ, Sudlow C, et al.; Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am J Epidemiol* 2017;**186**(9):1026-1034. doi: 10.1093/aje/kwx246.

36. Munafo MR, Tilling K, Taylor AE, et al.; Collider scope: when selection bias can substantially influence observed associations. *International Journal of Epidemiology* 2018;**47**(1):226-235.
37. Hughes RA, Davies NM, Davey Smith G, et al.; Selection bias when estimating average treatment effects using one-sample instrumental variable analysis. *Epidemiology* 2019;**30**(3):350-357. doi: 10.1097/EDE.0000000000000972.
38. Amrein K, Scherkl M, Hoffmann M, et al.; Vitamin D deficiency 2.0: an update on the current status worldwide. *Eur J Clin Nutr* 2020;**74**(11):1498-1513. doi: 10.1038/s41430-020-0558-y.
39. *Vitamin D: call for evidence*. <https://www.gov.uk/government/consultations/vitamin-d-call-for-evidence> (Date Accessed, date last accessed)

Accepted Manuscript

Table 1: Characteristics (Mean(SD)/N(%)) of UK Biobank study participants included in analyses

	Males	Females
N	172,171 (46.7%)	196,719 (53.3%)
<i>Outcome</i>		
Grip strength (kg)*	41.9 (8.9)	25.2 (6.3)
<i>Exposure</i>		
25(OH)D (nmol/L)	49.9 (21.1)	49.8 (20.9)
<i>Determinants of 25(OH)D</i>		
Month of blood draw		
January-March	43,655 (25.4)	47,179 (24.0)
April-June	48,896 (28.4)	58,624 (29.8)
July-September	40,104 (23.3)	47,564 (24.2)
October-December	39,516 (23.0)	43,352 (22.0)
Vitamin D supplementation [‡]		
No	164,311 (95.4)	179,023 (91.0)
Yes	7,860 (4.6)	17,696 (9.0)
<i>Potential confounders</i>		
Age (years)**	57.7 (39-73)	57.0 (40-71)
BMI (kg/m ²)	27.8 (4.23)	27.0 (5.15)
Townsend deprivation index ^{‡‡}	-1.54 (2.98)	-1.59 (2.88)
Smoking		
Never	84,488 (49.1)	117,122 (59.5)
Previous	67,608 (39.3)	62,675 (31.9)

Current	20,075 (11.7)	16,922 (8.6)
---------	---------------	--------------

*maximum of left and right hand measures; ‡ defined as a positive response to (i) taking a multivitamin or vitamin D supplement in the last 24 hours, (ii) regular supplementation with vitamin D or (iii) self-reported medical treatment with vitamin D products e.g. calciferol, ergocalciferol, calcifediol, calcitriol (oral or injection; with or without calcium); ** Range; † Positive values indicate areas with high deprivation; negative values indicate relative affluence

Accepted Manuscript

Figure titles and legends

Figure 1: Mean differences (95% CI) in grip strength (kg) by circulating 25-hydroxyvitamin D: (a) observational and (b) genetic associations in males

Legend to Figure 1: The dot represents the reference point of circulating 25-hydroxyvitamin D (50 nmol/L). Observational associations adjusted for potential confounders (smoking, BMI, deprivation, and age) and established determinants of circulating 25(OH)D (vitamin D supplementation and month of blood draw). Genetic associations were adjusted for established determinants of circulating 25(OH)D (vitamin D supplementation and month of blood draw) and genetic ancestry (i.e., 10 genetic principal components).

Figure 2: Mean differences (95% CI) in grip strength (kg) by circulating 25-hydroxyvitamin D: (a) observational and (b) genetic associations in females

Legend to Figure 2: The dot represents the reference point of circulating 25-hydroxyvitamin D (50 nmol/L). Observational associations adjusted for potential confounders (smoking, BMI, deprivation, and age) and established determinants of circulating 25(OH)D (vitamin D supplementation and month of blood draw). Genetic associations were adjusted for established determinants of circulating 25(OH)D (vitamin D supplementation and month of blood draw) and genetic ancestry (i.e., 10 genetic principal components).

Figure 3: Mean differences (95% CI) in grip strength (kg) by circulating 25-hydroxyvitamin D from age-stratified observational analysis in males


Legend to Figure 3: The dot represents the reference point of circulating 25-hydroxyvitamin D (50 nmol/L); associations adjusted for potential confounders (smoking, BMI, deprivation, and age) and established determinants of circulating 25(OH)D (vitamin D supplementation and month of blood draw).

Figure 4: Mean differences (95% CI) in grip strength (kg) by circulating 25-hydroxyvitamin D from age-stratified observational analysis in females

Legend to Figure 4: The dot represents the reference point of circulating 25-hydroxyvitamin D (50 nmol/L); associations adjusted for potential confounders (smoking, BMI, deprivation, and age) and established determinants of circulating 25(OH)D (vitamin D supplementation and month of blood draw).


Accepted Manuscript

Figure 1




Accepted Manuscript

Figure 2




Accepted Manuscript

Figure 3



Accepted Manuscript

Figure 4



Accepted Manuscript